Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: Trapianto di Fegato da Donatore Vivente Per Metastasi Epatiche Non Resecabili da Adenocarcinoma Del Colon]
This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM. Secondary outcomes are graft survival and donor outcomes in terms of safety and quality of life. Donor selection is performed according to the currently used Institutional and National standards and protocols.
• Age ≥18.
• Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma.
• Pathological classification of primary tumor as pT1-3, without peritoneal tumor deposits, absence of mucinous component \>50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type.
• No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET/CT scans.
• Liver metastases not eligible for curative liver resection
• Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete \[CR\] or partial response \[PR\] or standard disease \[SD\]) during second- line treatment for at least 4 months.
• Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant.
• Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2.
• Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national/local regulations.